Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|March 28, 2017
Maintaining Adherence as Out of Pocket Costs Rise
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how specialty pharmacy can help patients manage high out of pocket costs for specialty drugs.
Advertisement
Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how specialty pharmacy can help patients manage high out of pocket costs for specialty drugs.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5